HR19042 capsule ( DrugBank: - )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
66IgA腎症2

66. IgA腎症


臨床試験数 : 275 薬物数 : 258 - (DrugBank : 82) / 標的遺伝子数 : 36 - 標的パスウェイ数 : 140
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05016323
(ClinicalTrials.gov)
September 9, 202117/8/2021A Study to Evaluate the Efficacy and Safety of HR19042 Capsules in the Treatment of Primary IgA Nephropathy.A Randomized, Double-blind, Multicenter, Placebo-controlled, Parallel Groups, Phase II Clinical Trial to Evaluate the Efficacy and Safety of HR19042 Capsules in the Treatment of Primary IgA Nephropathy.IgA NephropathyDrug: HR19042 Capsules;Drug: PlaceboJiangsu HengRui Medicine Co., Ltd.NULLRecruiting18 YearsN/AAll210Phase 2China
2NCT04887532
(ClinicalTrials.gov)
July 1, 202113/5/2021A Trial of HR19042 Capsule in Healthy Chinese SubjectsSafety and Pharmacokinetics of HR19042 Capsule After Single Administration in Healthy Chinese SubjectsPrimary IgA NephropathyDrug: HR19042 capsuleJiangsu HengRui Medicine Co., Ltd.NULLCompleted18 Years45 YearsAll12Phase 1China